{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Symetine is a benzylamine derivative patented by Eli Lilly & Co. as an antiparasitic and antispirochete agent. In preclinical models, Symetine effectively suppresses amebic liver abscess in guinea pigs.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Denibulin is a novel antineoplastic agent. Denibulin selectively targets and reversibly binds to the colchicine-binding site on tubulin and inhibits microtubule assembly. This results in the disruption of the cytoskeleton of tumor endothelial cells, ultimately leading to cell cycle arrest, blockage of cell division and apoptosis. This causes inadequate blood flow to the tumor and eventually leads to a decrease in tumor cell proliferation. Denibulin hydrochloride had been in phase I clinical trials for the treatment of solid tumours. It was generally well tolerated and showed decrease in tumor vascular parameters. However, no recent development has been reported.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Benzotript, a cholecystokinin antagonist is an anti-gastrinic.
Status:
Investigational
Source:
INN:vipivotide tetraxetan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01019824: Phase 3 Interventional Completed Pain
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Priralfinamide, also known as Ralfinamide, FCE-26742A; NW-1029; PNU-0154339E, is a Na-channel blocker for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. Priralfinamide is in phase Ⅲ clinical trials by Newron for the treatment of chronic neuropathic pain.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Loxoribine [RWJ 217C7] is an immunostimulant which was developed by Johnson and Johnson. It is a selective agonist for TLR7 (Toll-like receptor 7), which possesses antitumor and antiviral properties and was investigated in a rat model of endometriosis and in addition, in phase I of a clinical trial for patients with advanced cancer.
Status:
Investigational
Source:
NCT00131430: Phase 2/Phase 3 Interventional Completed Obesity and Obesity-related Medical Conditions
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Taranabant is a highly selective cannabinoid-1 (CB1) receptor inverse agonist developed by Merck & Co for the treatment of obesity. The Phase III taranabant study involved about 2,400 patients and was to be conducted for two years. In March 2008, after completion of 52 weeks of the study, Merck reported positive results of the drug in conjunction with diet and exercise in obese patients. The patients experienced double the amount of weight loss by taking 2mg of taranabant when compared to the patients treated with placebo. However, in October 2008, the company discontinued the Phase III programme and clinical development of taranabant because of its side effects. The drug showed gastrointestinal and psychiatric side effects such as increased anxiety, depression and irritability. Merck had previously planned to file for regulatory approval with the US Food and Drug Administration in 2008, but subsequently withdrew it.
Status:
Investigational
Source:
NCT04135495: Phase 2 Interventional Completed Cystic Fibrosis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02511197: Early Phase 1 Interventional Unknown status Pulmonary Fibrosis, Unspecified
(2015)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lividomycin is the antibacterial agent produced by Streptomyces lividus. It is aminoglycoside antibiotic. Lividomycin binds to bacterial ribosomes and inhibits protein synthesis. In vitro development of resistance to lividomycin in P. aeruginosa and M. tuberculosis was much slower than that to kanamycin, but was comparable in Staphylococcus aureus. Lividomycin showed a positive protecting effect for the experimental infections in mice with several bacteria such as S. aureus, P. aeruginosa, Klebsiella pneumoniae and Escherichia coli. It was fairly effective for the experimental infection with the kanamycin-resistant strains of E. coli and P. aeruginosa producing the kanamycin-phosphorylating enzyme.
